Gluten-Related Disorders: Celiac Disease, Non-Celiac Gluten Sensitivity (NCGS), and Wheat Allergy – Diagnostics and Nutrition

Clear clinical taxonomies define distinct immune mechanisms triggered by cereal grains:

• Celiac Disease: An immune-mediated systemic enteropathy driven by dietary gluten in genetically susceptible individuals expressing major histocompatibility complex class II molecules HLA-DQ2 or HLA-DQ8. Deamidation of gliadin peptides by tissue transglutaminase 2 (tTG-2) triggers an adaptive CD4+ T-helper cascade and intraepithelial cytotoxic CD8+ lymphocyte infiltration, culminating in progressive enterocyte villous atrophy and crypt hyperplasia.
• Wheat Allergy: An adverse IgE-mediated immunological reaction to diverse wheat protein fractions (albumins, globulins, omega-5-gliadin). Manifests as acute urticaria, contact dermatitis, bronchospasm, or wheat-dependent exercise-induced anaphylaxis (WDEIA).
• Non-Celiac Gluten/Wheat Sensitivity (NCGS): Diagnosed when wheat ingestion provokes gastrointestinal and systemic manifestations (chronic fatigue, arthralgias, cephalalgia, cognitive fog) in the validated absence of celiac autoantibodies and wheat IgE. Pathogenesis implicates innate immune activation by wheat amylase-trypsin inhibitors (ATIs) and osmotic fermentation of cereal fructans.

Diagnostic evaluation for celiac disease must strictly precede any dietary gluten restriction:

• The Mandatory Gluten Challenge: Patients must sustain normal daily gluten intake (minimum 3–10 g gluten, equivalent to 2–4 wheat bread slices daily for at least 6 to 8 weeks) prior to diagnostic phlebotomy and endoscopy. Premature gluten withdrawal induces rapid serological negativity and mucosal healing, confounding diagnosis.
• Primary Serological Algorithm: Quantifying IgA antibodies against tissue transglutaminase (anti-tTG IgA) paired with total serum IgA measurement to rule out selective IgA deficiency (prevalent in 2%–3% of celiacs; if IgA is deficient, IgG-based deamidated gliadin peptide anti-DGP IgG or anti-tTG IgG must be ordered). Endomysial antibodies (EMA IgA) provide confirmatory specificity.
• Duodenal Mucosal Biopsy: Multiple endoscopic biopsy specimens (1–2 from the bulb, 4 from the distal duodenum) staged according to the modified Marsh-Oberhuber classification (Marsh 3 demonstrating characteristic villous blunting and intraepithelial lymphocytosis >25 IELs/100 enterocytes).
• Immunogenetics (HLA-DQ2.5 and HLA-DQ8): Exhibits a negative predictive value approaching 99%. Absence of both heterodimers decisively excludes celiac disease, although presence is common (30%–40% of general cohorts) and insufficient for positive diagnosis.

Strict, lifelong nutritional elimination of gluten represents the sole therapeutic cure for celiac disease:

• Legal Standard for Gluten-Free Status: Under Codex Alimentarius and EU Regulation 828/2014, products labeled 'gluten-free' must contain <20 parts per million (ppm, 20 mg/kg) of gluten, designated by the international Crossed Grain trademark.
• Strictly Prohibited Grains: All ancestral and modern wheat cultivars (spelt, emmer, einkorn, Khorasan/Kamut, durum), rye, barley (including barley malt extracts in cereals, confections, and beer), and uncertified commercial oats.
• Naturally Gluten-Free Cereals and Pseudocereals: Buckwheat, millet, rice, maize, quinoa, amaranth, teff, sorghum, cassava/tapioca, and certified gluten-free purity-protocol oats (well-tolerated by >95% of celiacs without avenin cross-reaction).
• Cross-Contact Prevention Hygiene: Dedicated kitchen appliances (toasters, bread makers), non-porous cutting boards, thorough sanitization of prep surfaces, and segregation of communal condiments to prevent microscopic crumb cross-contamination.